167 related articles for article (PubMed ID: 15914281)
1. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Ito T; Ouchida M; Morimoto Y; Yoshida A; Jitsumori Y; Ozaki T; Sonobe H; Inoue H; Shimizu K
Cancer Lett; 2005 Jun; 224(2):311-9. PubMed ID: 15914281
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
Savickiene J; Treigyte G; Borutinskaite V; Navakauskiene R; Magnusson KE
Ann N Y Acad Sci; 2006 Dec; 1091():368-84. PubMed ID: 17341629
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
Sawa H; Murakami H; Kumagai M; Nakasato M; Yamauchi S; Matsuyama N; Tamura Y; Satone A; Ide W; Hashimoto I; Kamada H
Acta Neuropathol; 2004 Jun; 107(6):523-31. PubMed ID: 15024582
[TBL] [Abstract][Full Text] [Related]
8. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo].
Xu DB; Wang YL; Yue Y; Wu SC; Ding H
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
Hoshino I; Matsubara H; Akutsu Y; Nishimori T; Yoneyama Y; Murakami K; Komatsu A; Sakata H; Matsushita K; Ochiai T
Oncol Rep; 2007 Sep; 18(3):585-92. PubMed ID: 17671705
[TBL] [Abstract][Full Text] [Related]
11. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
[TBL] [Abstract][Full Text] [Related]
12. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.
Sasakawa Y; Naoe Y; Sogo N; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2005 Feb; 69(4):603-16. PubMed ID: 15670579
[TBL] [Abstract][Full Text] [Related]
13. Depsipeptide (FK228) inhibits growth of human prostate cancer cells.
Lai MT; Yang CC; Lin TY; Tsai FJ; Chen WC
Urol Oncol; 2008; 26(2):182-9. PubMed ID: 18312939
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
Cao H; Stamatoyannopoulos G
Am J Hematol; 2006 Dec; 81(12):981-3. PubMed ID: 16888791
[TBL] [Abstract][Full Text] [Related]
15. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
16. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis.
Yamamura K; Ohishi K; Katayama N; Yu Z; Kato K; Masuya M; Fujieda A; Sugimoto Y; Miyata E; Shibasaki T; Heike Y; Takaue Y; Shiku H
Br J Haematol; 2006 Oct; 135(2):242-53. PubMed ID: 16939493
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
